These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17195089)

  • 1. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
    VanOosten RL; Earel JK; Griffith TS
    Apoptosis; 2007 Mar; 12(3):561-71. PubMed ID: 17195089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL; Earel JK; Griffith TS
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Vanoosten RL; Moore JM; Ludwig AT; Griffith TS
    Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.
    El-Zawahry A; Lu P; White SJ; Voelkel-Johnson C
    Cancer Gene Ther; 2006 Mar; 13(3):281-9. PubMed ID: 16167063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S; Yoshida T; Horinaka M; Shiraishi T; Wakada M; Sakai T
    Oncogene; 2004 Aug; 23(37):6261-71. PubMed ID: 15208660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
    Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC
    Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
    Kim DR; Park MY; Lee CS; Shim SH; Yoon HI; Lee JH; Sung MW; Kim YS; Lee CT
    Cancer Gene Ther; 2011 Jul; 18(7):467-77. PubMed ID: 21455254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL.
    Kaminskyy VO; Surova OV; Vaculova A; Zhivotovsky B
    Carcinogenesis; 2011 Oct; 32(10):1450-8. PubMed ID: 21771726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
    Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
    Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.
    Inoue H; Shiraki K; Ohmori S; Sakai T; Deguchi M; Yamanaka T; Okano H; Nakano T
    Int J Mol Med; 2002 May; 9(5):521-5. PubMed ID: 11956660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.